Ibufenac

CHEMBL341812 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
192.2 g/mol
LogP
3.1
Phase
4

This early nonsteroidal anti-inflammatory drug (NSAID) was withdrawn from the market due to serious liver toxicity, but it paved the way for the development of safer drugs like ibuprofen. It worked by inhibiting prostaglandin synthesis to reduce pain and inflammation.

Molecular Weight

192.2500 g/mol

LogP

3.10

TPSA

37.30 Ų

Lipinski RO5

Pass

Mechanism of Action

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)Cc1ccc(CC(=O)O)cc1

InChI

InChI=1S/C12H16O2/c1-9(2)7-10-3-5-11(6-4-10)8-12(13)14/h3-6,9H,7-8H2,1-2H3,(H,13,14)

Molecular Formula

C12H16O2

HBD / HBA

1 / 2

Rotatable Bonds

4

Heavy Atoms

14

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

This early nonsteroidal anti-inflammatory drug (NSAID) was withdrawn from the market due to serious liver toxicity, but it paved the way for the development of safer drugs like ibuprofen. It worked by inhibiting prostaglandin synthesis to reduce pain and inflammation.

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Yes, Ibufenac is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL341812. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 15250. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.